Gastric Cancer as Preventable Disease

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 12, 2017, Pages 1833-1843

  Rugge, Massimo ^a,b   Genta, Robert M ^c   Di Mario, Francesco ^d   El Omar, Emad M ^e   El Serag, Hashem B ^c   Fassan, Matteo ^a   Hunt, Richard H ^f   Kuipers, Ernst J ^g   Malfertheiner, Peter ^h   Sugano, Kentaro ⁱ   Graham, David Y ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b Tumor Registry of the Veneto Region   (Italy)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PARMA   (Italy)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f MCMASTER UNIVERSITY   (Canada)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h OTTO VON GUERICKE UNIVERSITY   (Germany)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Gastric Cancer; Gastritis; Helicobacter pylori; Primary Prevention; Secondary Prevention

Indexed keywords

ACETYLSALICYLIC ACID; HELICOBACTER PYLORI VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEPSINOGEN I; PEPSINOGEN II; PROTON PUMP INHIBITOR;

ARTICLE; ATROPHIC GASTRITIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CHRONIC GASTRITIS; ENDOSCOPY; ERADICATION THERAPY; FAMILY HISTORY; HELICOBACTER INFECTION; HUMAN; INTESTINE METAPLASIA; MUCOSA INFLAMMATION; NON INVASIVE MEASUREMENT; NONHUMAN; PRECANCER; PRIMARY PREVENTION; SECONDARY PREVENTION; STOMACH ATROPHY; STOMACH CANCER; STOMACH CARCINOGENESIS; COMPLICATION; GASTRITIS; STOMACH TUMOR;

GASTRITIS; HELICOBACTER INFECTIONS; HUMANS; STOMACH NEOPLASMS;

EID: 85021967442     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2017.05.023     Document Type: Article

References (129)

1. DeSantis, C.E., Lin, C.C., Mariotto, A.B., et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64 (2014), 252–271.
2. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014), 202–209.
3. Graham, D.Y., Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 148 (2015), 719–731.e3.
4. Piazuelo, M.B., Epplein, M., Correa, P., Gastric cancer: an infectious disease. Infect Dis Clin North Am 24 (2010), 853–869 vii.
5. Hunt, R.H., Camilleri, M., Crowe, S.E., et al. The stomach in health and disease. Gut 64 (2015), 1650–1668.
6. Rugge, M., Correa, P., Dixon, M.F., et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 16 (2002), 1249–1259.
7. Rugge, M., Correa, P., Dixon, M.F., et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 24 (2000), 167–176.
8. Correa, P., Haenszel, W., Cuello, C., et al. A model for gastric cancer epidemiology. Lancet 2 (1975), 58–60.
9. Correa, P., Gastric cancer: overview. Gastroenterol Clin North Am 42 (2013), 211–217.
10. Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3 (2017), 524–548.
11. Bosman, F.T., Carneiro, F., Hruban, R.H., et al. World Health Organization classification of tumours of the digestive system. 2010, IARC Press, Lyon.
12. Tsukanov, V.V., Butorin, N.N., Maady, A.S., et al. Helicobacter pylori infection, intestinal metaplasia, and gastric cancer risk in eastern Siberia. Helicobacter 16 (2011), 107–112.
13. Anderson, W.F., Camargo, M.C., Fraumeni, J.F. Jr., et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 303 (2010), 1723–1728.
14. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Personal habits and indoor combustions: volume 100 E—a review of human carcinogens. IARC monographs on the evaluation of carcinogenic risks to humans/World Health Organization, International Agency for Research on Cancer 100 (2012), 1–538.
15. Cavaleiro-Pinto, M., Peleteiro, B., Lunet, N., et al. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control 22 (2011), 375–387.
16. Rugge, M., Genta, R.M., Graham, D.Y., et al. Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. Gut 65 (2016), 721–725.
17. Nordenstedt, H., Graham, D.Y., Kramer, J.R., et al. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol 108 (2013), 65–71.
18. Genta, R.M., Sonnenberg, A., Helicobacter-negative gastritis: a distinct entity unrelated to Helicobacter pylori infection. Aliment Pharmacol Ther 41 (2015), 218–226.
19. Chen, X.Z., Chen, H., Castro, F.A., et al. Epstein-Barr virus infection and gastric cancer: a systematic review. Medicine, 94, 2015, e792.
20. Tsugane, S., Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer Sci 96 (2005), 1–6.
21. Gonzalez, C.A., Pera, G., Agudo, A., et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 107 (2003), 629–634.
22. Tramacere, I., Negri, E., Pelucchi, C., et al. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 23 (2012), 28–36.
23. Buckland, G., Travier, N., Huerta, J.M., et al. Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int J Cancer 137 (2015), 598–606.
24. Tsubono, Y., Nishino, Y., Komatsu, S., et al. Green tea and the risk of gastric cancer in Japan. N Engl J Med 344 (2001), 632–636.
25. MacLean, C.H., Newberry, S.J., Mojica, W.A., et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 295 (2006), 403–415.
26. Gonzalez, C.A., Agudo, A., Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer 130 (2012), 745–753.
27. Hanada, K., Graham, D.Y., Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma. Expert Rev Anticancer Ther 14 (2014), 947–954.
28. Kimura, K., Takemoto, T., An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1 (1969), 87–97.
29. Weis, V.G., Goldenring, J.R., Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer 12 (2009), 189–197.
30. Rugge, M., Correa, P., Di Mario, F., et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 40 (2008), 650–658.
31. Capelle, L.G., de Vries, A.C., Haringsma, J., et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 71 (2010), 1150–1158.
32. Sugano, K., Tack, J., Kuipers, E.J., et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64 (2015), 1353–1367.
33. Coati, I., Fassan, M., Farinati, F., et al. Autoimmune gastritis: pathologist's viewpoint. World J Gastroenterol 21 (2015), 12179–12189.
34. Kaplan, H.S., Riger, L.G., Pernicious anemia and carcinoma of the stomach: autopsy study concerning their relationship. Am J Med Sci 209 (1945), 339–348.
35. Murphy, G., Dawsey, S.M., Engels, E.A., et al. Cancer risk after pernicious anemia in the US elderly population. Clin Gastroenterol Hepatol 13 (2015), 2282–2289.e4.
36. Rugge, M., Fassan, M., Pizzi, M., et al. Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther 35 (2012), 1460–1466.
37. Fassan, M., Baffa, R., Kiss, A., Advanced precancerous lesions within the GI tract: the molecular background. Best Pract Res Clin Gastroenterol 27 (2013), 159–169.
38. Rugge, M., Cassaro, M., Di Mario, F., et al. The long term outcome of gastric non-invasive neoplasia. Gut 52 (2003), 1111–1116.
39. Rugge, M., Capelle, L.G., Cappellesso, R., et al. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol 27 (2013), 205–223.
40. Marshall, B.J., Warren, J.R., Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1 (1984), 1311–1315.
41. Chang, Y.W., Han, Y.S., Lee, D.K., et al. Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients. Int J Cancer 101 (2002), 469–474.
42. Brenner, H., Bode, G., Boeing, H., Helicobacter pylori infection among offspring of patients with stomach cancer. Gastroenterology 118 (2000), 31–35.
43. Mayerle, J., den Hoed, C.M., Schurmann, C., et al. Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA 309 (2013), 1912–1920.
44. Roma-Giannikou, E., Karameris, A., Balatsos, B., et al. Intrafamilial spread of Helicobacter pylori: a genetic analysis. Helicobacter 8 (2003), 15–20.
45. Kuipers, E.J., Lundell, L., Klinkenberg-Knol, E.C., et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334 (1996), 1018–1022.
46. Malfertheiner, P., Megraud, F., O'Morain, C.A., et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 61 (2012), 646–664.
47. Wong, B.C., Zhang, L., Ma, J.L., et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 61 (2012), 812–818.
48. Ye, X., Fu, J., Yang, Y., et al. Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PloS One, 8, 2013, e71522.
49. Singh, P.P., Singh, S., Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 24 (2013), 1721–1730.
50. Burucoa, C., Delchier, J.C., Courillon-Mallet, A., et al. Comparative evaluation of 29 commercial Helicobacter pylori serological kits. Helicobacter 18 (2013), 169–179.
51. Ricci, C., Holton, J., Vaira, D., Diagnosis of Helicobacter pylori: invasive and non-invasive tests. Best Pract Clin Gastroenterol 21 (2007), 299–313.
52. Gisbert, J.P., de la Morena, F., Abraira, V., Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 101 (2006), 1921–1930.
53. Ferwana, M., Abdulmajeed, I., Alhajiahmed, A., et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol 21 (2015), 1305–1314.
54. Kuipers, E.J., Perez-Perez, G.I., Meuwissen, S.G., et al. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 87 (1995), 1777–1780.
55. Kuipers, E.J., In through the out door: serology for atrophic gastritis. Eur J Gastroenterol Hepatol 15 (2003), 877–879.
56. Agreus, L., Kuipers, E.J., Kupcinskas, L., et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 47 (2012), 136–147.
57. Yanaoka, K., Oka, M., Mukoubayashi, C., et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 17 (2008), 838–845.
58. Yanaoka, K., Oka, M., Yoshimura, N., et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer 123 (2008), 917–926.
59. Enomoto, S., Maekita, T., Ohata, H., et al. Novel risk markers for gastric cancer screening: present status and future prospects. World J Gastrointest Endosc 2 (2010), 381–387.
60. Rugge, M., de Boni, M., Pennelli, G., et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 31 (2010), 1104–1111.
61. Dixon, M.F., Genta, R.M., Yardley, J.H., et al. Classification and grading of gastritis: the updated Sydney System—International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20 (1996), 1161–1181.
62. Dinis-Ribeiro, M., Areia, M., de Vries, A.C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 44 (2012), 74–94.
63. Kato, M., Kaise, M., Yonezawa, J., et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. Gastrointest Endosc 72 (2010), 523–529.
64. Ezoe, Y., Muto, M., Uedo, N., et al. Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. Gastroenterology 141 (2011), 2017–2025.e3.
65. Capelle, L.G., Haringsma, J., de Vries, A.C., et al. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. Dig Dis Sci 55 (2010), 3442–3448.
66. Uedo, N., Ishihara, R., Iishi, H., et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy 38 (2006), 819–824.
67. Kaneko, K., Oono, Y., Yano, T., et al. Effect of novel bright image enhanced endoscopy using blue laser imaging (BLI). Endosc Int Open 2 (2014), E212–E219.
68. Kikuste, I., Marques-Pereira, R., Monteiro-Soares, M., et al. Systematic review of the diagnosis of gastric premalignant conditions and neoplasia with high-resolution endoscopic technologies. Scand J Gastroenterol 48 (2013), 1108–1117.
69. Song, J., Zhang, J., Wang, J., et al. Meta-analysis: narrow band imaging for diagnosis of gastric intestinal metaplasia. PloS One, 9, 2014, e94869.
70. Morson, B.C., Sobin, L.H., Grundmann, E., et al. Precancerous conditions and epithelial dysplasia in the stomach. J Clin Pathol 33 (1980), 711–721.
71. Ming, S.C., Bajtai, A., Correa, P., et al. Gastric dysplasia: significance and pathologic criteria. Cancer 54 (1984), 1794–1801.
72. Riddell, R.H., Iwafuchi, M., Problems arising from eastern and western classification systems for gastrointestinal dysplasia and carcinoma: are they resolvable?. Histopathology 33 (1998), 197–202.
73. Goldstein, N.S., Lewin, K.J., Gastric epithelial dysplasia and adenoma: historical review and histological criteria for grading. Hum Pathol 28 (1997), 127–133.
74. Lauwers, G.Y., Riddell, R.H., Gastric epithelial dysplasia. Gut 45 (1999), 784–790.
75. Nagayo, T., Histological diagnosis of biopsied gastric mucosae with special reference to that of borderline lesions. Gann Monogr 11 (1971), 245–256.
76. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. First English ed. Tokyo: Kanehara & Co., Ltd; 1995.
77. Rugge, M., Capelle, L.G., Fassan, M., Individual risk stratification of gastric cancer: evolving concepts and their impact on clinical practice. Best Pract Res Clin Gastroenterol 28 (2014), 1043–1053.
78. Schlemper, R.J., Riddell, R.H., Kato, Y., et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47 (2000), 251–255.
79. Fenoglio-Preiser, C.M., Carneiro, F., Correa, P., et al. Gastric carcinoma. Hamilton, S.R., Aaltonen, L.A., (eds.) Pathology and genetics, tumors of the digestive system, 3rd ed., 2000, IARC Press, Lyon, 39–52.
80. de Vries, A.C., van Grieken, N.C., Looman, C.W., et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 134 (2008), 945–952.
81. You, W.C., Li, J.Y., Blot, W.J., et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer 83 (1999), 615–619.
82. Zagari, R.M., Romano, M., Ojetti, V., et al. Guidelines for the management of Helicobacter pylori infection in Italy: the III Working Group Consensus Report 2015. Dig Liver Dis 47 (2015), 903–912.
83. Choi, I.J., Endoscopic gastric cancer screening and surveillance in high-risk groups. Clin Endosc 47 (2014), 497–503.
84. Rugge, M., Farinati, F., Baffa, R., et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study—Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 107 (1994), 1288–1296.
85. Rugge, M., Leandro, G., Farinati, F., et al. Gastric epithelial dysplasia: how clinicopathologic background relates to management. Cancer 76 (1995), 376–382.
86. Park, Y.M., Cho, E., Kang, H.Y., et al. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc 25 (2011), 2666–2677.
87. Lian, J., Chen, S., Zhang, Y., et al. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. Gastrointest Endosc 76 (2012), 763–770.
88. Chia, N.Y., Tan, P., Molecular classification of gastric cancer. Ann Oncol 27 (2016), 763–769.
89. Tan, P., Yeoh, K.G., Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology 149 (2015), 1153–1162.e3.
90. Hanada, K., Uchida, T., Tsukamoto, Y., et al. Helicobacter pylori infection introduces DNA double-strand breaks in host cells. Infect Immun 82 (2014), 4182–4189.
91. Rugge, M., Bersani, G., Bertorelle, R., et al. Microsatellite instability and gastric non-invasive neoplasia in a high risk population in Cesena, Italy. J Clin Pathol 58 (2005), 805–810.
92. Fassan, M., Simbolo, M., Bria, E., et al. High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer 17 (2014), 442–449.
93. Dong, B., Xie, Y.Q., Chen, K., et al. Differences in biological features of gastric dysplasia, indefinite dysplasia, reactive hyperplasia and discriminant analysis of these lesions. World J Gastroenterol 11 (2005), 3595–3600.
94. Shiao, Y.H., Rugge, M., Correa, P., et al. P53 alteration in gastric precancerous lesions. Am J Pathol 144 (1994), 511–517.
95. Anagnostopoulos, G.K., Stefanou, D., Arkoumani, E., et al. Immunohistochemical expression of cell-cycle proteins in gastric precancerous lesions. J Gastroenterol Hepatol 23 (2008), 626–631.
96. Fassan, M., Mastracci, L., Grillo, F., et al. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 61 (2012), 769–776.
97. De Falco, M., Lucariello, A., Iaquinto, S., et al. Molecular mechanisms of Helicobacter pylori pathogenesis. J Cell Physiol 230 (2015), 1702–1707.
98. Ferreira, R.M., Machado, J.C., Figueiredo, C., Clinical relevance of Helicobacter pylori vacA and cagA genotypes in gastric carcinoma. Best Pract Res Clin Gastroenterol 28 (2014), 1003–1015.
99. Hayashi, Y., Tsujii, M., Wang, J., et al. CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesis. Gut 62 (2013), 1536–1546.
100. Motoyama, K., Inoue, H., Nakamura, Y., et al. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 14 (2008), 2334–2340.
101. Fassan, M., Saraggi, D., Balsamo, L., et al. Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis. Oncotarget 7 (2016), 4915–4924.
102. Lee, K.J., Inoue, M., Otani, T., et al. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 118 (2006), 2315–2321.
103. Gong, E.J., Ahn, J.Y., Jung, H.Y., et al. Risk factors and clinical outcomes of gastric cancer identified by screening endoscopy: a case-control study. J Gastroenterol Hepatol 29 (2014), 301–309.
104. Malfertheiner, P., Sipponen, P., Naumann, M., et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 100 (2005), 2100–2115.
105. Zeng, M., Mao, X.H., Li, J.X., et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386 (2015), 1457–1464.
106. D'Elios, M.M., Czinn, S.J., Immunity, inflammation, and vaccines for Helicobacter pylori. Helicobacter 19:Suppl 1 (2014), 19–26.
107. Blanchard, T.G., Czinn, S.J., Current status and prospects for a Helicobacter pylori vaccine. Gastroenterol Clin North Am 44 (2015), 677–689.
108. Parsonnet, J., Harris, R.A., Hack, H.M., et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 348 (1996), 150–154.
109. Fendrick, A.M., Chernew, M.E., Hirth, R.A., et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 159 (1999), 142–148.
110. Roderick, P., Davies, R., Raftery, J., et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 10 (2003), 148–156.
111. Wong, B.C., Lam, S.K., Wong, W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291 (2004), 187–194.
112. Fuccio, L., Zagari, R.M., Eusebi, L.H., et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 151 (2009), 121–128.
113. Lee, Y.C., Chen, T.H., Chiu, H.M., et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 62 (2013), 676–682.
114. Lee, Y.C., Chiang, T.H., Liou, J.M., et al. Mass eradication of Helicobacter pylori to prevent gastric cancer: theoretical and practical considerations. Gut Liver 10 (2016), 12–26.
115. Ford, A.C., Forman, D., Hunt, R.H., et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ, 348, 2014, g3174.
116. Fock, K.M., Talley, N., Moayyedi, P., et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 23 (2008), 351–365.
117. Asaka, M., Kato, M., Takahashi, S., et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 15 (2010), 1–20.
118. International Agency for Research on Cancer. Helicobacter pylori eradication as a strategy for preventing gastric cancer, 2014, WHO Press, World Health Organization, Geneva, Switzerland.
119. Rugge, M., Genta, R.M., Staging and grading of chronic gastritis. Hum Pathol 36 (2005), 228–233.
120. Hamashima, C., Shibuya, D., Yamazaki, H., et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 38 (2008), 259–267.
121. Hamashima, C., Shabana, M., Okada, K., et al. Mortality reduction from gastric cancer by endoscopic and radiographic screening. Cancer Sci 106 (2015), 1744–1749.
122. Sugano, K., Screening of gastric cancer in Asia. Best Pract Res Clin Gastroenterol 29 (2015), 895–905.
123. National Cancer Center. The Japanese guidelines for gastric cancer screening 2014. Promotion of evidence-based cancer screening. [Cited 3 Jul 2017] (In Japanese) Available at: http://canscreen.ncc.go.jp/.
124. Watabe, H., Mitsushima, T., Yamaji, Y., et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 54 (2005), 764–768.
125. Yamaguchi, Y., Nagata, Y., Hiratsuka, R., et al. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels: the ABC method. Digestion 93 (2016), 13–18.
126. Gotoda, T., Ishikawa, H., Ohnishi, H., et al. Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy. Gastric Cancer 18 (2015), 605–611.
127. Lee, S., Jun, J.K., Suh, M., et al. Gastric cancer screening uptake trends in Korea: results for the National Cancer Screening Program from 2002 to 2011—a prospective cross-sectional study. Medicine, 94, 2015, e533.
128. Choi, K.S., Jun, J.K., Park, E.C., et al. Performance of different gastric cancer screening methods in Korea: a population-based study. PloS One, 7, 2012, e50041.
129. Pan, K.F., Zhang, L., Gerhard, M., et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut 65 (2016), 9–18.